

STIC-ILL

From: Davis, Minh-Tam
Sent: Thursday, December 09, 1999 2:46 PM
To: STIC-ILL
Subject: Reprint request

For 09/387340

- 1) Evans GF, 1994, J Lipid res, 35(9): 1634-45.
- 2) Schodel, F, 1992, J Virol, 66(1): 106-14.
- 3) Tarar Mr, 1996, FEMS Immunol and medical microbiol. 16(3-4): 183-192.
- 4) Roy, P, 1996, J Lipid Res, 37(1): 22-34.
- 5) Thomas, AP, 1996, Hybridoma, 15(5): 359-64.

Thank you.

Minh-Tam Davis
ART UNIT 1642, Room 8A01
305-2008

\$20.00

✓

ADONIS - Electronic Journal Services

Requested by

Adonis

Article title	Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein
Article identifier	0928824497001554
Authors	Tarar_M_R Emery_V_C Harrison_T_J
Journal title	FEMS Immunology and Medical Microbiology
ISSN	0928-8244
Publisher	Elsevier Netherlands
Year of publication	1996
Volume	16
Issue	3-4
Supplement	0
Page range	183-192
Number of pages	10
User name	Adonis
Cost centre	Development
PCC	\$20.00
Date and time	Thursday, December 09, 1999 5:15:47 PM

Copyright © 1991-1999 ADONIS and/or licensors.

The use of this system and its contents is restricted to the terms and conditions laid down in the Journal Delivery and User Agreement. Whilst the information contained on each CD-ROM has been obtained from sources believed to be reliable, no liability shall attach to ADONIS or the publisher in respect of any of its contents or in respect of any use of the system.



Expression of a human cytomegalovirus gp58 antigenic domain fused to the hepatitis B virus nucleocapsid protein

Maryam R. Tarar^a, Vincent C. Emery^b, Tim J. Harrison^{a,*}

^a University Department of Medicine, The Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK

^b Department of Virology, The Royal Free Hospital School of Medicine, Rowland Hill Street, London NW3 2PF, UK

Received 11 December 1995; revised 23 August 1996; accepted 26 August 1996

Abstract

Hepatitis B virus core antigen (HBcAg) has been used as a carrier for expression and presentation of a variety of heterologous viral epitopes in particulate form. The aim of this study was to produce hybrid antigens comprising HBcAg and an immunogenic epitope of human cytomegalovirus (HCMV). A direct comparison was made of amino and carboxyl terminal fusions in order to investigate the influence of position of the foreign epitope on hybrid core particle formation, antigenicity and immunogenicity. HCMV DNA encoding a neutralising epitope of the surface glycoprotein gp58 was either inserted at the amino terminus or fused to the truncated carboxyl terminus of HBcAg and expressed in *Escherichia coli*. The carboxyl terminal fusion (HBc₃₋₁₄₄-HCMV) was expressed at high levels and assembled into core like particles resembling native HBcAg. Protein with a similar fusion at the amino terminus (HCMV-HBc₁₋₁₈₃) could not be purified or characterised immunologically, although it formed core like particles. HBc₃₋₁₄₄-HCMV displayed HBc antigenicity but HCMV antigenicity could not be detected by radioimmunoassay or western blotting using anti-HCMV monoclonal antibody 7-17 or an anti-HCMV human polyclonal antiserum. Following immunisation of rabbits with HBc₃₋₁₄₄-HCMV, a high titre of anti-HBc specific antibody was produced along with lower titres of HCMV/gp58 specific antibody.

Keywords: Prokaryotic expression; Fusion protein; Hepatitis B core antigen; Human cytomegalovirus; Envelope glycoprotein

1. Introduction

The use of HBcAg to present the foreign epitopes to the immune system offers several advantages. It can be expressed in a wide range of systems, including bacterial [1,2], insect [3], mammalian [4] and yeast [5] cells and recombinant vaccinia viruses [6]. In addition, HBcAg is highly immunogenic, acting as a T-cell independent and T-cell dependent antigen [7]. Furthermore, both the amino [6,8] and carboxyl

[9,10] termini of HBcAg have been used separately to express several fusion proteins.

The amino terminus of HBcAg has been fused to amino acids 141–160 of the VP1 protein of foot and mouth disease virus (FMDV) serotype O₁. Although the recombinant protein proved to be toxic for *Escherichia coli*, it has been expressed efficiently using a vaccinia virus system to give rise to a highly immunogenic, particulate product [6]. Subsequently, an *E. coli* expression vector, pBC404 was developed with gene expression driven by the *tac* promoter [11]. Using this vector, an immunogenic epitope of

* Corresponding author.

poliovirus type 1 [11] and an epitope of the human rhinovirus type 2 capsid polypeptide VP2 [12] have been expressed in *E. coli* and found to be highly immunogenic. Similarly, heterologous amino acid sequences of variable length have been fused to a truncated carboxyl terminus and expressed as recombinant core particles in *E. coli* [9,10]. The coding sequences inserted in different constructs include those for preS1 (aa 1–20 and 1–36), preS2 (aa 109–134) and S (aa 111–156 and 111–165) epitopes of HBV. In addition, synthetic sequences coding for fragments of the transmembrane region (gp41) of the HIV-1 envelope protein have been expressed [9]. These fusion proteins were synthesised in *E. coli* yielding stable products which assembled to form particles morphologically similar to HBcAg. The proteins exhibit the immunogenic characteristics of the HBcAg epitopes and the epitopes carried by the additional sequences [9].

The amino and truncated carboxyl termini of HBcAg have been used separately for fusion of foreign epitopes in independent expression systems. Schödel et al. [13], used epitopes derived from preS1 and preS2 sequences of HBV and fused these in separate constructs to the amino and carboxyl terminus of HBcAg. Their results suggested that polypeptides fused to the amino terminus of HBcAg may not be expressed on the surface of core particles. The objective of this study was to compare the expression in *E. coli*, of a foreign sequence (a sequence encoding one of the neutralizing epitopes, gp58, of HCMV), fused to the amino or the truncated carboxyl terminus of HBcAg.

2. Materials and methods

2.1. Construction of expression plasmids

Amino terminal fusion: Plasmid p73HCMV comprises 149 bp of HCMV DNA encoding an immunodominant epitope of the surface glycoprotein gp58, derived from strain AD169 and cloned into the vector pT7T3/18U (Pharmacia Biotec, Uppsala). This HCMV sequence was amplified using the polymerase chain reaction (PCR) and primers which had *EcoRI* and *BamHI* restriction enzyme sites incorporated at their 5' ends (Fig. 1). The product was

double digested with *EcoRI/BamHI*, and ligated to similarly digested plasmid pPV404 [11], yielding plasmid pv404CMV. Poliovirus sequences in pPV404 were removed by the digestion with *EcoRI/BamHI*. The integrity of the sequences across the junction sites in plasmid pv404CMV was confirmed by sequencing.

Carboxyl terminal fusion: HCMV sequences were amplified from plasmid p73HCMV using another primer pair with *HindIII* and *BamHI* restriction enzyme sites at their 5' ends (Fig. 1). The PCR product was double digested with *HindIII* and *BamHI* and ligated into similarly digested plasmid ptaC_{HpaII}-R2 [9], forming recombinant plasmid ptaC_{CMV}. The integrity of the junction sites was confirmed by sequencing.

2.2. Protein purification


Cultures of *E. coli* strain RB791 (lac I^q) harbouring parental and recombinant plasmids were induced with IPTG and the proteins purified by chromatography on sepharose 4B-CL and ultracentrifugation [2,9]. The purified proteins were stained with Coomassie blue after resolution using SDS-PAGE and western blotting was carried out as described by Towbin et al. [14].

2.3. Immunisation of animals

The fusion protein (30 mg) was diluted in 0.5 ml PBS and 0.5 ml of complete Freund's adjuvant (CFA) for immunisation or the same volume of incomplete Freund's adjuvant (IFA) for booster injections. Three outbred Dutch male rabbits (6 months of age; 1.5 kg) were immunised intramuscularly with the fusion protein emulsified in CFA on day 0 and subsequently boosted with the fusion protein emulsified in IFA on days 30, 60 and 90. Blood was collected from rabbits on days 0 (preimmune; PI), 10 (first test bleed; ITB), 40 (second test bleed; 2TB) 70 (third test bleed; 3TB) and 100 (fourth test bleed; 4TB).

2.4. Murine monoclonal antibodies

RFHBc17, the generous gift of Dr. J.A. Waters, is believed to recognise a major epitope of HBcAg and



Schematic representation of plasmid construction of *ptacCMV* and *pv404CMV*. MCS, multiple cloning site; T3&T7, phage promoters; AMP, ampicillin resistance gene; ori, origin of replication; Tac, tac promoter [▨▨▨▨]; polio, poliovirus sequences [▨▨▨▨]; Trp, Trp promoter [▨▨▨▨]; Lac + HBcAg gene, Lac promoter and hepatitis B core antigen gene [▨▨▨▨]; TC, tetracycline resistance gene [▨▨▨▨]. Position of some restriction enzyme sites are shown as black lines cutting across the plasmid.

Fig. 1.

reacts with native and recombinant (expressed in *E. coli*) antigen, but not with HBcAg [15]. Other anti-HBc monoclonals were the gift of Dr. E. Korec — 18C H₅G₁ and 18C E₁₁B₁₂, which react with native and recombinant HBcAg; 35H2, which reacts with HBcAg, as well as native and recombinant HBcAg; and A2C12, which reacts with HBcAg but not native or recombinant HBcAg [16,17].

Monoclonal anti-HCMV, 7-17, was the generous gift of Dr. W. Britt, University of Alabama at Birmingham, USA. This recognition site for this antibody is within the immunodominant AD-1 region of gp58 [18].

2.5. Radioimmunoassays (RIA) and immunofluorescence

To determine HBc and HCMV antigenicity of the fusion proteins, polystyrene beads coated with rabbit anti-HBc antibody were used in a modification of a sandwich RIA described previously [2]. A second antibody was then added; either mouse monoclonal anti-HBc, for HBc antigenicity assay, or human polyclonal HCMV antibody or mouse monoclonal anti-HCMV for HCMV antigenicity assay. Depending on the type of the second antibody used, further incubation was carried out with iodinated sheep anti-mouse or anti-human antibody.

Western blots were carried out following purification of recombinant proteins by ammonium sulphate precipitation and sepharose CL-4B chromatography. After separation on 12.5% SDS-polyacrylamide gels (without 2-mercaptoethanol), the polypeptides were transferred to nitrocellulose using standard methods.

A competitive radioimmunoassay was used to detect anti-HBc antibody in test sera, as described by Murray et al. [19]. Test serum dilutions (1 in 10, 1 in 30, 1 in 100) and positive and negative controls were incubated overnight with HBcAg coated beads in the presence of iodinated human anti-HBc IgG.

Anti-HCMV antibodies were detected in rabbit sera using immunofluorescence. Insect cells (Sf21) infected with a recombinant baculovirus expressing glycoprotein B (gB) of HCMV (the generous gift of Dr. W. Britt, University of Alabama at Birmingham, USA) were fixed to glass slides. The cells were incubated with preimmune or immune rabbit sera at dilutions of 1 in 10, 1 in 20, 1 in 40, 1 in 60, 1 in 80

and 1 in 100. Uninfected Sf21 cells were used as a control. Only sera obtained from the third and fourth test bleeds were tested against HCMVgB-infected and uninfected Sf21 cells. Reactivity between insect cell expressed gB and anti-HCMV specific antibody in rabbit sera was detected by using fluorescein isothiocyanate (FITC) conjugated anti-rabbit IgG.

3. Results

3.1. Amino terminal fusion

Plasmids pPV404 and pv404CMV were grown in *E. coli* and the *tac* promoter was induced. The expressed proteins, PV-HBc₁₋₁₈₃ (a poliovirus fusion protein) and HCMV-HBc₁₋₁₈₃ were visualised by Coomassie blue staining after SDS-PAGE and compared with uninduced cell extracts (Fig. 2a). Expression of a protein with molecular weight of 24–26 kDa (Fig. 2a, lane 2) was detected in cells harbouring the control plasmid pPV404. A fusion protein corresponding to HCMV-HBc₁₋₁₈₃ protein could not be detected (Fig. 2a, lane 4). Although further purification was not carried out for the HCMV-HBc₁₋₁₈₃ protein, examination by electron microscopy revealed relatively few core-like particles (Fig. 2c) compared with control cultures (Fig. 2b). HCMV-HBc₁₋₁₈₃ fusion protein when analysed by dot blot (results not shown) and western blot immunoassays using a panel of anti-HBc monoclonal antibodies (results only shown for one monoclonal antibody; Fig. 4, lane 4), did not demonstrate any HBcAg reactivity, although the control PV-HBc₁₋₁₈₃ fusion protein did react with all anti-HBc monoclonal antibodies tested (Fig. 4, lane 3).

3.2. Carboxyl terminal fusion

Gene expression in ptaCpall-R2 also is driven by the *tac* promoter. The plasmid is engineered so that it contains the initiation codon of the β -galactosidase gene fused to the third codon of HBcAg. The plasmid contains the coding sequence for the first 144 amino acid residues of HBcAg (thereby deleting aa 145–183) and a *Hind*III site is present at this position to facilitate ligation to other sequences [9] (Fig. 1). Therefore, a primer pair (CMV1 and CMV2)




Fig. 2. (A) SDS-PAGE and Coomassie blue staining of proteins expressed after IPTG-induction of cultures harbouring plasmids pPV404 (poliovirus-HBc₁₋₁₈₃ amino terminal fusion) and pv404CMV (HCMV-HBc₁₋₁₈₃ amino terminal fusion). Lane 1, PV-HBc₁₋₁₈₃ pre-IPTG induction; lane 2, PV-HBc₁₋₁₈₃ post-IPTG induction (band marked with an arrow); lane 3, HCMV-HBc₁₋₁₈₃ pre-IPTG induction; lane 4, HCMV-HBc₁₋₁₈₃ post-IPTG induction; lane 5, protein molecular weight markers in kilodaltons (kDa). (B and C) Electron micrographs showing core-like particles in IPTG-induced cultures of cells harbouring plasmids pv404CMV (HCMV-HBc₁₋₁₈₃, panel B) and pPV404 (PV-HBc₁₋₁₈₃, panel C). Size bar = 100 nm.

containing *Eco*RI and *Bam*HI sites was used to amplify HCMV sequences from p73HCMV. The nucleotide sequence at the junction sites was confirmed and protein expression was induced with IPTG as described in Section 2. Proteins of 18 kDa, representing truncated HBcAg₃₋₁₄₄, and 22 kDa, corresponding to the HBc₃₋₁₄₄-HCMV fusion protein, were visualised by SDS-PAGE/Coomassie blue staining (Fig. 3a). The difference in mobility between the truncated HBcAg₃₋₁₄₄ and the HBc₃₋₁₄₄-HCMV fusion protein is in good agree-

ment with that predicted from the length of amino acid sequence encoded by the HCMV insert. It was observed that some truncated HBcAg₃₋₁₄₄ and HBc₃₋₁₄₄-HCMV protein was also present in the uninduced cell extracts (Fig. 3a, lanes 2 and 4). This could be explained by the relatively low amounts of the lac repressor in this strain of *E. coli*, leading to constitutive expression of the proteins.

The truncated HBcAg₃₋₁₄₄ and HBc₃₋₁₄₄-HCMV proteins were purified by chromatography and ultracentrifugation and visualised by SDS-PAGE and Coomassie blue staining. Yields ranged from 2 to 10 mg/l of culture. Success of the method employed to purify the HBcAg fusion proteins by pelleting using ultracentrifugation indicates that the fusion protein is assembled into core-like particles. The particles were visualised using electron microscopy and resemble recombinant HBcAg particles produced in *E. coli* (Fig. 3b, c).

HBc antigenicity of the HBc₃₋₁₄₄-HCMV fusion protein was analysed by dot blot (data not shown), western blot and RIA. The (rabbit) polyclonal anti-HBc antiserum recognised the truncated HBcAg₃₋₁₄₄ and HBc₃₋₁₄₄-HCMV fusion protein in monomeric, dimeric and high molecular weight forms in a western blot (results not shown). However, of a panel of five anti-HBc monoclonal antibodies, only one, RFHBc17, detected HBc₃₋₁₄₄-HCMV in a western blot (Fig. 4, lane 2). Three of the monoclonal antibodies detected the protein in a dot blot assay (results not shown), suggesting conformational changes to several exposed HBc epitopes may have resulted during SDS-PAGE. The HBc reactivity of HBc₃₋₁₄₄-HCMV also was analysed by a sandwich RIA using a solid phase coated with polyclonal rabbit anti-HBc IgG, showing a dose-response binding to anti-HBc labelled beads similar to that produced by truncated HBcAg₃₋₁₄₄ (Fig. 5). The signal generated in this antigen capture RIA was high using truncated HBcAg₃₋₁₄₄ and between 1–100 ng of antigen could be detected. When HBc₃₋₁₄₄-HCMV was used, the signal generated was not as high as that with the control and more antigen was required to produce a similar signal to the control antigen (Figs. 6 and 7).

Antigenicity of HBc₃₋₁₄₄-HCMV could not be demonstrated using anti-HCMV monoclonal 7-17 or anti-HCMV human polyclonal antibodies in dot blot




Fig. 3. (A) SDS-PAGE and Coomassie blue staining of proteins expressed after IPTG-induction of cultures harbouring ptacHpaII-R2 (truncated HBcAg₁₋₁₄₄) and ptacCMV (HBc₁₋₁₄₄-HCMV). Lane 1, protein molecular weight markers in kDa; lane 2, truncated HBcAg₁₋₁₄₄ pre-IPTG induction; lane 3, truncated HBcAg₁₋₁₄₄ post-IPTG induction (band marked with an arrow); lane 4, HBc₁₋₁₄₄-HCMV pre-IPTG induction; lane 5, HBc₁₋₁₄₄-HCMV post-IPTG induction (band marked with an arrow). (B and C) Electron micrographs showing core-like particles in IPTG-induced cultures of cells harbouring plasmids ptacHpaII-R2 (truncated HBcAg₁₋₁₄₄, panel B) and ptacCMV (HBc₁₋₁₄₄-HCMV, panel C). Size bar = 50 nm.

and western blot assays. Furthermore, negative results were obtained using RIA in which the capturing solid phase was the same as that used for HBc

antigenicity, that is polystyrene beads coated with rabbit anti-HBc antibody but with the exception that the second antibody was either a monoclonal or a polyclonal anti-HCMV antibody. The failure to detect HCMV antigenicity suggests that the HCMV epitope might not be exposed on the surface of the hybrid core particles or have all of the amino acid residues required for conformational integrity.

3.3. Immunisation studies

All the animals mounted an efficient immune response against the fusion protein HBc₁₋₁₄₄-HCMV




Fig. 4. Western blot analysis of HBc₁₋₁₄₄-HCMV and HCMV-HBc₁₋₁₈₃ using anti-HBc monoclonal antibody RFHBc17. Purified protein samples were separated by 12.5% SDS-PAGE and transferred to a nitrocellulose membrane. HBc reactivity was detected by using polyclonal rabbit anti-HBc serum with the alkaline phosphatase conjugate detection system. Lane 1, truncated HBcAg₁₋₁₄₄; lane 2, HBc₁₋₁₄₄-HCMV; lane 3, PV-HBc₁₋₁₈₃; lane 4, HCMV-HBc₁₋₁₈₃; lane 5, protein molecular weight markers in kDa.




Fig. 5. Sandwich RIA to determine HBc antigenicity of HBc₁₋₁₄₄-HCMV (■) and truncated HBcAg₁₋₁₄₄ (▲).

and produced anti-HBc antibodies, which were detected 10 days after commencing immunisation. A maximal anti-HBc response was achieved at day 40, ten days after the first booster injection and this antibody level was maintained or increased slightly after the second booster injection on day 60 (Fig. 6). The fourth test bleed obtained on day 100 was not analysed for anti-HBc response. Although all the rabbits produced a similar response, the anti-HBc levels in rabbit 732 were higher than the other two rabbits. As one of the rabbits (R730) died from a chest infection on day 65, it was not possible to analyse a third test bleed from this animal.

Although HCMV antigenicity had not been detected so far, immunofluorescence studies confirmed the presence of anti-HCMVgB specific antibodies in the rabbit sera. Strong cytoplasmic immunofluorescence was detected when immune rabbit serum from the third and the fourth test bleeds was incubated with insect cells which express gB. This reactivity was detectable at a one in sixty dilution of the serum. Only weak immunofluorescence that was diffusely spread in the insect cell was seen when preimmune serum was used as a control. Similar non




Fig. 6. Induction of anti-HBc antibody in rabbits immunised with HBc₃₋₁₄₄-HCMV, determined using a competitive RIA. Rabbits R730, R731 and R732 were immunised with HBc₃₋₁₄₄-HCMV on days 0, 30, 60 and 90 and the serum samples were obtained on day 0, 10, 40, 70 and 100. Sera were diluted 1 in 10 (■), 1 in 30 (▲) and 1 in 100 (●) and tested in duplicate for the presence of anti-HBc antibody by competitive RIA. A high titre positive control serum obtained from R86 immunised with HBcAg diluted 1 in 10 (□), 1 in 30 (△) and 1 in 100 (○) and assayed concomitantly. Signal/noise (S/N) ratio is indicated as a broken line.




Fig. 7. Detection by immunofluorescence of anti-HCMV specific antibody in rabbit sera. Sf21 cells infected with a recombinant baculovirus expressing HCMVgB were fixed to the glass slide and incubated with immune or preimmune rabbit sera. FITC conjugated anti-rabbit antibody was added to detect any reactivity between HCMVgB and rabbit sera. (A) Positive control: anti-HCMVgB-specific antibody (C23) against Sf21 cells expressing HCMVgB. (B) Serum from R731 (fourth test bleed) against Sf21 cells expressing HCMVgB. (C) Preimmune serum from R731 against Sf21 cells expressing HCMVgB. (D) Serum from R731 against uninfected Sf21 cells.

specific fluorescence was noted when immune rabbit serum was tested against uninfected insect cells. These results provide evidence that HCMV-gp58

epitope was immunogenic when presented to the immune system with HBcAg.

4. Discussion

HBcAg fusion proteins have been expressed in *E. coli* and purified on the basis of their assembly into core-like particles [2,9]. Although the same method was employed here, the results suggest that amino terminal fusion protein HCMV–HBc_{1–183} either was not expressed or was expressed only in very low quantities, as the protein could not be detected by Coomassie blue staining, dot blot immunoassays or western blotting. In a study by Shiau [20], inability to purify HBcAg fusion proteins containing sequences encoding the S, preS1 and preS2 regions of HBV, and carrying inserts at both amino and carboxyl termini of truncated HBcAg, was attributed to protein aggregation due to some inherent properties of the foreign epitope. Utz et al. [21] reported that a stretch of amino acids in HCMV–gp58 that bind to the HCMV neutralising antibody 7-17 are hydrophobic and, indeed, this characteristic has been displayed in hydrophobicity profiles [22], generated for the amino and carboxyl terminal fusions with HBcAg. The hydrophobic nature of the gp58 epitope could explain the poor solubility of the recombinant polypeptide. Although HCMV–HBc_{1–183} could not be purified for immunological study, the observation of particles by electron microscopy suggested that the fusion protein is capable of assembling into core particles.

The carboxyl terminal fusion HBc_{3–144}–HCMV and the control, truncated HBcAg (HBcAg_{3–144}) display a similar HBc reactivity in several assays, indicating that fusion of foreign sequences to the carboxyl terminus of HBcAg does not abrogate HBc antigenicity. In western blotting, only one anti-HBc monoclonal (RFHBc17) reacted with HBc_{3–144}–HCMV and the control proteins. The same solid support was used for binding the fusion protein in western and dot blot formats. In western blotting, however, the protein would probably not be in the native form, since it was denatured by treatment with ionic detergent and boiling under reducing conditions. Although electrophoretic transfer of the protein to the nitrocellulose membrane could remove the

detergent and the reducing agent, the covalent forces which result in binding of the protein to the membrane may prevent complete renaturation of the polypeptide. Therefore, it is likely that western blotting would favour linear determinants [20]. This suggests that monoclonal RFHBc17 recognises a linear determinant whereas the other monoclonal antibodies may recognise a conformational determinant/s present only on the native HBcAg. This hypothesis is supported by the fact that the antibody was raised against HBcAg purified from infected chimpanzee liver and following treatment with 0.1% SDS and 0.1% 2-mercaptoethanol at 37°C for 2 h [15]. In the antigen capture RIA using rabbit polyclonal anti-HBc antibody, HBc_{3–144}–HCMV displayed a similar antigenicity to the control truncated HBcAg_{3–144}. Although the signal generated was weaker for HBc_{3–144}–HCMV than for the control, these results are in accordance with the previous findings that HBc antigenicity is retained in carboxyl terminal fusions [9,10,13].

The HCMV–gp58 epitope was found not to be antigenic in either dot blot immunoassays or SDS–PAGE immunoblotting using anti-HCMV monoclonal and (human) polyclonal antibodies. The absence of reactivity with anti-HCMV antibodies raises the possibility that the HCMV epitope might not have been expressed at all. However, the results obtained by sequencing both fusion constructs indicate that there was no stop codon or disruption of the reading frame that could have prevented the expression of the fusion proteins. Instability or misfolding of a hybrid polypeptide has been the main impediment to the development of generally applicable strategies for chimeric particle formation [23]. A similar problem may have arisen in this study due to presence of hydrophobic domains in the gp58 epitope. This suggestion is strengthened by the finding in this study that gp58 antigenicity was not preserved and could have resulted from misfolding of the hybrid polypeptide in such a way that HBcAg B-cell epitopes were exposed on the surface of the particle but gp58 epitopes were masked, being sequestered inside the particle. The apparent loss of gp58 antigenicity observed for both fusion proteins supports the hypothesis of conformational change attributable to the hydrophobic nature of this region of gp58. Thus, it is possible that addition of a hydrophobic

amino acids has altered the topology molecule in a way that inhibits its assembly into a hybrid core particle. It also is interesting to note that more recent data have shown that the immunodominant region AD-1 of gp58, which contains the recognition site for monoclonal antibody 7-17, comprises around seventy amino acid residues [18]. Thus, conformational integrity required for recognition by 7-17 may be lacking in the fifty residue HCMV peptide sequence used in these experiments.

The HBc and HCMV immunogenicity of HBc₃₋₁₄₄-HCMV was determined in terms of antibody production in rabbits. Immunisation of rabbits with HBc₃₋₁₄₄-HCMV produced high levels of HBcAg-specific antibodies, indicating that fusion of the HCMV-gp58 epitope to the carboxyl terminus of HBcAg had not altered the immunogenicity of HBcAg. Although all the immunised rabbits mounted a strong immune response to the core component of the HBc₃₋₁₄₄-HCMV fusion protein, determined using RIA, the antibody response to the HCMV epitope could not be analysed or compared because of the lack of availability of appropriate antigens that could be used in RIA. Therefore, anti-HCMV antibodies initially were analysed using an Abbott CMV latex agglutination test but the results were non-specific (results not shown). This was followed by immunofluorescence using insect cells infected with a recombinant baculovirus expressing HCMV gp58. The presence of anti-HCMV specific antibodies was confirmed using this technique and immunofluorescence produced by the immune rabbit sera provides the evidence that the HCMV epitope is immunogenic, although these antibodies were of low titre.

In conclusion, two separate fusions were constructed between HCMV-gp58 and the amino and carboxyl termini of HBcAg. When expressed in *E. coli*, HBc antigenicity was retained only by the HBcAg carboxyl terminal fusion and HCMV antigenicity could not be detected for either fusion. The immunogenicity of the HBcAg carboxyl terminal fusion was determined by antibody production in rabbits. The results demonstrate that immunisation of rabbits with the fusion protein resulted in generation of HBcAg-specific and HCMV-specific antibodies. The HBcAg-specific antibodies were produced only a few days after the primary immunisation whereas

anti-HCMV response was delayed. Nevertheless this indicates that HBcAg can serve as a carrier for presentation of HCMV-gp58 epitope to the immune system emphasising the potential value of this epitope, perhaps in a larger form, as a candidate for a subunit HCMV vaccine.

Acknowledgements

We are most grateful to Professor Sir Kenneth Murray FRS for invaluable advice and help and for supplying the plasmid ptaCHpall-R2 and also to Sandra Bruce and Mike Dyson, at the Institute of Cell and Molecular Biology, University of Edinburgh, where the latter part of these studies was carried out. We also thank Dr. B.E. Clarke, Dr. J. Waters, Dr. E. Korec and Dr. W. Britt for supplying the plasmids and monoclonal antibodies used in this study. We are grateful to Stella Bury and Glynnis Leadbetter of the Departments of Biochemistry and Medical Microbiology, University of Edinburgh, for electron microscopy and immunisation studies, respectively. MRT was supported by a scholarship grant from Ministry of Science and Technology, Government of Pakistan.

References

- [1] Pasek, M., Goto, T., Gilbert, W., Zink, B., Schaller, H., MacKay, P., Leadbetter, G. and Murray, K. (1979) Hepatitis B virus genes and their expression in *E. coli*. *Nature* 282, 575–579.
- [2] Stahl, S., MacKay, P., Magazin, M., Bruce, S.A. and Murray, K. (1982) Hepatitis B virus core antigen: Synthesis in *Escherichia coli* and application in diagnosis. *Proc. Natl. Acad. Sci. U.S.A.* 79, 1606–1610.
- [3] Lanford, R.E., Kennedy, R.C., Dreesman, G.R., Eichberg, J.W., Notvall, L., Luckow, V.A. and Summers, M.D. (1988) Expression of hepatitis B surface and core antigens using a baculovirus expression vector. In: *Viral Hepatitis and Liver Disease* (Zuckerman, A.J., Ed.), pp. 372–378. Alan R. Liss, Inc, New York.
- [4] Roossinck, M.J., Jameel, S., Loukin, S.H. and Siddiqui, A. (1986) Expression of hepatitis B viral core region in mammalian cells. *Mol. Cell. Biol.* 6, 1393–1400.
- [5] Kniskern, P.J., Hagopian, A., Montgomery, D.L., Burke, P., Dunn, N.R., Hofmann, K.J., Miller, W.J. and Ellis, R.W. (1986) Unusually high-level expression of a foreign gene (hepatitis B virus core antigen) in *Saccharomyces cerevisiae*. *Gene* 46, 135–141.

- [6] Clarke, B.E., Newton, S.E., Carroll, A.R., Francis, M.J., Appleyard, G., Syred, A.D., Highfield, P.E., Rowlands, D.J. and Brown, F. (1987) Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein. *Nature* 330, 381–384.
- [7] Milich, D.R. and McLachlan, A. (1986) The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen. *Science* 234, 1398–1401.
- [8] Francis, M.J., Hastings, G.Z., Brown, A.L., Grace, K.G., Rowlands, D.J., Brown, F. and Clarke, B.E. (1990) Immunological properties of hepatitis B core antigen fusion proteins. *Proc. Natl. Acad. Sci. U.S.A.* 87, 2545–2549.
- [9] Stahl, S.J. and Murray, K. (1989) Immunogenicity of peptide fusions to hepatitis B virus core antigen. *Proc. Natl. Acad. Sci. U.S.A.* 86, 6283–6287.
- [10] Borisova, G.P., Berzins, I., Pushko, P.M., Pumpen, P., Gren, E.J., Tsibinogin, V.V., Loseva, V., Ose, V., Ulrich, R., Siakkou, H. et al. (1989) Recombinant core particles of hepatitis B virus exposing foreign antigenic determinants on their surface. *FEBS Lett.* 259, 121–124.
- [11] Francis, M.J. and Clarke, B.E. (1989) Peptide vaccines based on enhanced immunogenicity of peptide epitopes presented with T-cell determinants or hepatitis B core protein. *Meth. Enzymol.* 178, 659–676.
- [12] Francis, M.J., Hastings, G.Z., Brown, A.L., Grace, K.G., Rowlands, D.J., Brown, F. and Clarke, B.E. (1990). Immunological properties of hepatitis B core antigen fusion proteins. *Proc. of the National Academy of Sciences. U.S.A. Proc. Natl. Acad. Sci. U.S.A.* 87, 2545–2549.
- [13] Schödel, F., Moriarty, A.M., Peterson, D.L., Zheng, J., Hughes, J.L., Will, H., Leturcq, D.J., McGee, J.S. and Milich, D.R. (1992) The position of heterologous epitopes inserted in hepatitis B virus core particles determines their immunogenicity. *J. Virol.* 66, 106–114.
- [14] Towbin, H., Staehelin, T. and Gordon, J. (1979) Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. *Proc. Natl. Acad. Sci. U.S.A.* 76, 4350–4354.
- [15] Waters, J.A., Jowett, T.P. and Thomas H.C. (1986) Identification of a dominant immunogenic epitope of the nucleocapsid (HBc) of the hepatitis B virus. *J. Med. Virol.* 19, 79–86.
- [16] Hlozanek, I., Korec, E., Dostalova, V., Stara, J., König, J., Bichko, V.V., Siechertova, A. and Gren, E.J. (1987) Monoclonal antibodies against genetically manipulated hepatitis B core antigen. *Folia Biol. Prague* 33, 295–300.
- [17] Korec, E. and Gerlich, W.H. (1992) HBc and HBe specificity of monoclonal antibodies against complete and truncated HBc proteins from *E. coli*. *Arch. Virol. (Suppl.)* 4, 119–121.
- [18] Wagner, B., Kropff, B., Kalbacher, H., Britt, W., Sundqvist, V.A., Ostberg, L. and Mach, M. (1992) A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus. *J. Virol.* 66, 5290–5297.
- [19] Murray, K., Bruce, S.A., Hinnen, A., Wingfield, P., van Erd, P.M. and de Reus, A. (1984) Hepatitis B virus antigens made in microbial cells immunise against viral infection. *EMBO J.* 3, 645–650.
- [20] Shiau, A.L. (1993) Immunological aspects of hepatitis B virus core antigen and its derivatives. Ph.D. Thesis, University of Edinburgh.
- [21] Utz, U., Britt, W., Vugler, L. and Mach, M. (1989) Identification of a neutralising epitope on glycoprotein gp58 of human cytomegalovirus. *J. Virol.* 63, 1995–2001.
- [22] Kyte, J. and Doolittle, R.F. (1982) A simple method for displaying the hydropathic character of a protein. *J. Mol. Biol.* 157, 105–132.
- [23] Bruss, V. and Ganem, D. (1991) Mutational analysis of hepatitis B surface antigen particle assembly and secretion. *J. Virol.* 65, 3813–3820.